Genscript Biotech Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Genscript Biotech kazanç ve gelirin sırasıyla yıllık 91.9% ve 2.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 91% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 3.9% olacağı tahmin edilmektedir.

Anahtar bilgiler

91.9%

Kazanç büyüme oranı

91.04%

EPS büyüme oranı

Life Sciences kazanç büyümesi	29.9%
Gelir büyüme oranı	2.8%
Gelecekteki özkaynak getirisi	3.90%
Analist kapsamı	Good
Son güncelleme	25 Aug 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings

Sep 18

Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet

Sep 08

Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues

Jul 29

At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?

Jul 24

Global Demand Rebound Will Drive Life Sciences And CDMO Expansion

Jul 17 Expansion in global markets, technology upgrades, and industry partnerships are set to drive stronger growth, improved margins, and long-term earnings stability.

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

May 14

Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Apr 07

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Feb 12

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 20

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Nov 19

Kazanç ve Gelir Büyüme Tahminleri

SEHK:1548 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	921	295	80	239	10
12/31/2026	809	99	39	258	10
12/31/2025	949	66	89	222	8
6/30/2025	828	5	126	228	N/A
3/31/2025	711	-31	2	152	N/A
12/31/2024	594	-67	-121	76	N/A
6/30/2024	454	419	-276	-20	N/A
3/31/2024	507	421	-410	-153	N/A
12/31/2023	560	423	-543	-287	N/A
9/30/2023	773	-140	-506	-266	N/A
6/30/2023	707	-185	-523	-245	N/A
3/31/2023	667	-206	-431	-183	N/A
12/31/2022	626	-227	-339	-120	N/A
9/30/2022	598	-315	-321	-142	N/A
6/30/2022	570	-403	-304	-163	N/A
3/31/2022	530	-381	-289	-150	N/A
12/31/2021	490	-359	-274	-137	N/A
9/30/2021	483	-265	-265	-127	N/A
6/30/2021	454	-183	-256	-118	N/A
3/31/2021	422	-194	-268	-134	N/A
12/31/2020	391	-205	-279	-151	N/A
9/30/2020	354	-194	-171	-48	N/A
6/30/2020	318	-183	-64	54	N/A
3/31/2020	296	-140	-103	12	N/A
12/31/2019	273	-97	-142	-30	N/A
9/30/2019	257	-59	-207	-116	N/A
6/30/2019	241	-22	-272	-202	N/A
3/31/2019	236	0	N/A	53	N/A
12/31/2018	231	21	N/A	308	N/A
9/30/2018	216	24	N/A	338	N/A
6/30/2018	201	27	N/A	369	N/A
3/31/2018	177	26	N/A	195	N/A
12/31/2017	153	26	N/A	21	N/A
9/30/2017	139	27	N/A	24	N/A
6/30/2017	125	28	N/A	27	N/A
3/31/2017	120	27	N/A	30	N/A
12/31/2016	115	26	N/A	33	N/A
9/30/2016	107	26	N/A	29	N/A
6/30/2016	99	25	N/A	25	N/A
3/31/2016	93	21	N/A	22	N/A
12/31/2015	87	18	N/A	20	N/A
9/30/2015	82	13	N/A	18	N/A
6/30/2015	78	8	N/A	16	N/A
3/31/2015	74	7	N/A	14	N/A
12/31/2014	70	6	N/A	12	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1548 'nin tahmini kazanç büyümesi (yıllık 91.9% ) tasarruf oranının ( 2.7% ) üzerindedir.

Kazançlar ve Piyasa: 1548 şirketinin kazançlarının (yıllık 91.9% ) Hong Kong pazarından (yıllık 12.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 1548 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 1548 şirketinin gelirinin (yıllık 2.8% ) Hong Kong pazarından (yıllık 8.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1548 şirketinin gelirinin (yıllık 2.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1548 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 3.9 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/10/06 23:46
Gün Sonu Hisse Fiyatı	2025/10/06 00:00
Kazançlar	2025/06/30
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Genscript Biotech Corporation 15 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jin Zhang	China International Capital Corporation Limited
Shitong Han	Citic Securities Co., Ltd.
Zhu Chen	Citic Securities Co., Ltd.

Genscript Biotech Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Consensus revenue estimates fall by 19%

Consensus forecasts updated

Consensus forecasts updated

Recent updates

We Think You Can Look Beyond Genscript Biotech's (HKG:1548) Lackluster Earnings

New minor risk - Profit margin trend

Genscript Biotech (HKG:1548) Has A Pretty Healthy Balance Sheet

CEO & COO exercised options and sold HK$2.0m worth of stock

First half 2025 earnings released: US$0.012 loss per share (vs US$0.083 loss in 1H 2024)

GenScript Biotech Corporation Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

Genscript Biotech Corporation to Report First Half, 2025 Results on Aug 16, 2025

Now 22% undervalued

Genscript Biotech Corporation's (HKG:1548) 28% Price Boost Is Out Of Tune With Revenues

At HK$18.16, Is It Time To Put Genscript Biotech Corporation (HKG:1548) On Your Watch List?

Global Demand Rebound Will Drive Life Sciences And CDMO Expansion

Executive Chairman exercised options and sold HK$11m worth of stock

Executive Chairman exercised options and sold HK$4.9m worth of stock

Now 22% undervalued

CEO & COO exercised options and sold HK$4.1m worth of stock

Genscript Biotech Corporation Announces New 5-Year Survey Data for Carvykti in Cartitude-1 Study for Multiple Myeloma at 2025

Genscript Biotech Corporation Announces Board and Committee Changes, Effective 29 May 2025

Co-Founder exercised options and sold HK$22m worth of stock

Does Genscript Biotech (HKG:1548) Have A Healthy Balance Sheet?

Co-Founder exercised options and sold HK$39m worth of stock

Co-Founder exercised options and sold HK$52m worth of stock

Board Member recently sold HK$481k worth of stock

Genscript Biotech Corporation (HKG:1548) May Have Run Too Fast Too Soon With Recent 27% Price Plummet

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Genscript Biotech Corporation, Annual General Meeting, May 29, 2025

Genscript Biotech Corporation to Report Fiscal Year 2024 Results on Mar 11, 2025

Investors Still Aren't Entirely Convinced By Genscript Biotech Corporation's (HKG:1548) Revenues Despite 27% Price Jump

Genscript Biotech Corporation Announces Establishment of A Sub-Committee of the Risk Management and ESG Committee

Genscript Biotech Corporation (HKG:1548) Shares Could Be 49% Below Their Intrinsic Value Estimate

Executive Chairman exercised options and sold HK$5.5m worth of stock

Executive Chairman recently sold HK$396k worth of stock

Co-Founder exercised options and sold HK$53m worth of stock

Co-Founder exercised options and sold HK$43m worth of stock

Market Still Lacking Some Conviction On Genscript Biotech Corporation (HKG:1548)

Genscript Biotech Corporation Appoints Aylin Kosova Bilgin Has Joined as the First-Ever Chief Marketing Officer for GenScript Life Science Group

Board Member recently sold HK$901k worth of stock

Now 22% overvalued after recent price rise

Genscript Biotech Corporation Announces Late-Breaking Long-Term Overall Survival Data from Cartitude-4 Study in Multiple Myeloma

Genscript Biotech Corporation Announces Board Appointments

Consensus EPS estimates fall by 46%

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Genscript Biotech Corporation to Report First Half, 2024 Results on Aug 09, 2024

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings: EPS exceeds analyst expectations

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Consensus estimates of losses per share improve by 12%

Consensus EPS estimates upgraded to US$0.054 loss, revenue downgraded

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

New minor risk - Profitability

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

Executive Chairman recently sold HK$610k worth of stock

Executive Chairman exercised options and sold HK$4.5m worth of stock

Independent Non-Executive Director exercised options and sold HK$1.6m worth of stock

Non-Executive Director exercised options and sold HK$2.4m worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Consensus revenue estimates fall by 19%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 24% undervalued